Nicole Gaudelli has joined GV (Google Ventures), a corporate venture capital arm of US-based conglomerate Alphabet, as an entrepreneur in residence, Forbes reported.
A gene-editing specialist, Gaudelli previously worked at Beam Therapeutics, the US-based creator of gene editing technology CRISPR, where she held various positions including vice president of gene editing, senior director and head of gene editing platform technologies and senior scientist.
Gaudelli is also a postdoctoral researcher at Harvard University and Broad Institute of MIT where she specalised in base editing, which can cure thousands of rare diseases caused by point mutations.
Issi Rozen, general partner at GV, said that Gaudelli was a natural fit for the corporate venture firm given that her base editor technology is being used in two of the fund’s portfolio companies, Beam Therapeutics and Verve Therapeutics. “It’s been a great way for us to bet on really talented people that we believe can start very interesting companies,” Rozen told Forbes.
Google Ventures was founded in 2009. The firm invests in enterprise, life sciences and frontier technology sectors with 359 companies in its portfolio including Andela, Cosmos and Egnyte.